CompletedNot Applicable

Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"

Japan1,026 participantsStarted 2017-02-28

Plain-language summary

The purpose of this survey is to evaluate the long-term safety and efficacy of the alogliptin and metformin hydrochloride combination tablet in type 2 diabetes mellitus patients with renal impairment (mild), hepatic impairment (mild or moderate), or advanced age (65 years and more) in the routine clinical setting.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Have renal impairment (mild)
✓. Have hepatic impairment (mild or moderate)
✓. Elderly (aged 65 years or more)

What they're measuring

Percentage of Participants Who Had One or More Adverse Events

Timeframe: Up to 12 months

Trial details

NCT IDNCT03555565

SponsorTakeda

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2019-10-31

Results submitted2020-10-29

View on ClinicalTrials.gov More Type 2 Diabetes Mellitus trials